Khan A, Johnson F, Avery D H, Cohen S, Scherzo B, Dunner D L
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.
Am J Psychiatry. 1988 Sep;145(9):1153-6. doi: 10.1176/ajp.145.9.1153.
In two studies using the dexamethasone suppression test (DST) to evaluate the efficacy of newer antidepressants in depressed outpatients, the authors found a DST nonsuppression rate of 13% (11 of 86 patients). Thirty-three of the DST suppressors received an antidepressant and 42 received placebo; the drug-treated group showed a significant therapeutic response. The low rate of DST nonsuppression in these depressed outpatients, a finding consistent with that of other investigators, does not confirm or refute reports that these patients are relatively resistant to placebo in comparison with active medication. The authors recommend that DST results not be used as selection criteria in studies assessing newer therapies for depressed outpatients.
在两项使用地塞米松抑制试验（DST）来评估新型抗抑郁药对门诊抑郁症患者疗效的研究中，作者发现DST不抑制率为13%（86例患者中有11例）。33例DST抑制者接受了抗抑郁药治疗，42例接受了安慰剂治疗；药物治疗组显示出显著的治疗反应。这些门诊抑郁症患者中DST不抑制率较低，这一发现与其他研究者一致，但并未证实或反驳关于这些患者与活性药物相比对安慰剂相对耐药的报道。作者建议，在评估门诊抑郁症患者新型治疗方法的研究中，不应将DST结果用作选择标准。
